TP53 and in situ carcinoma: By integrating our cancer cell targeting, highly accumulating NIR dye with cytotoxic agent CIS, our group had previously developed a DZ-CIS conjugate that has shown significant efficacy on MYC-driven TP53 mutated CIS -resistant aggressive Burkitt’s lymphoma model [24].